Biotech | January 21, 2022
Palleon announces IND clearance for first-in-class cancer immunotherapy
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia
The company will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
The hospital will be operated under the name and style of Max Super Speciality Hospital, Dwarka
The extended collaboration will provide services relating to small molecules for both Forbion and BGV portfolio companies active in the biopharmaceutical space
The artificial cornea is 100% made of non-biological materials and require no co-implantation of donor corneas and it is an ideal option for treating patients with corneal blindness
Industry Report highlights the opportunities and need for multiple sectoral collaboration through 12 actionable recommendations under 6 thematic areas
He holds nine US patents and has published in multiple peer-reviewed journals and conferences
The tie-up combines Abbisko Therapeutics’ proprietary drug discovery platform with Lilly’s disease and discovery expertise
Subscribe To Our Newsletter & Stay Updated
